TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials 8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis Developed via multistage consensus process Higher pt enrollment potential? POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX

• https://x.com/RHEUMarampa/status/2063162488732934213/photo/1

Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya

• https://x.com/DrMiniDey/status/2063161469080846760/photo/1

Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR

• https://x.com/AurelieRheumo/status/2063143217885855817/photo/1

#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi

• 5 years since Patient ID001: Progress on CAR-T Therapy in RMD | RheumNow
• https://x.com/Yuz6Yusof/status/2063141761061400974/photo/1

Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort -17,669 early RA pts -7.3% BL depression -Median follow-up 1.2 years -No association w/ CV hospitalisation after adjustment (sHR 1.05) Reassuring short-term data, longer follow-up https://t.co/XmMVGY1VlI

• https://x.com/AurelieRheumo/status/2063141746825900497/photo/1

How many ‘cars’ are there? crowded #CAR-T ‘driving’ innovation at #EULAR2026 >90 abstracts w CAR-T in title Lessons learned Maybe #immune #reset is not always the goal ➡️vs ’#immune #dimming How long are effects? safety looks good PT selection is key Early, no damage @RheumNow https://t.co/6jii5MBJcJ

• https://x.com/Janetbirdope/status/2063008581935333473/photo/1
• https://x.com/Janetbirdope/status/2063008581935333473/photo/1
• https://x.com/Janetbirdope/status/2063008581935333473/photo/1

One of the highlights of #EULAR2026 for me: ♀️The "This Is a Woman's World" session I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬 https://t.co/3jwJIegGg4 via @YouTube @ArLARheumatolog https://t.co/Azvkl2sjdu

• This Is a Woman’s World: Women's Health in Rheumatic Disease
• https://x.com/Nellziade/status/2062965329496539425/photo/1

Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw

• https://x.com/AurelieRheumo/status/2062950853187695084/photo/1

Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270

#EULAR2026 Recommendations: Vasculitis -Confirm diagnosis with imaging and biopsy - Start GC early but with taper plan - For major flare again confirm dx and restart GC - Consider IL-6 or UPA - MTX may be option if biologics not available @RheumNow https://t.co/DqLZtW630y

• https://x.com/JihaRheum/status/2063174271061344591/photo/1

#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV

• https://x.com/Yuz6Yusof/status/2063192348499034168/photo/1

Core definitions when understanding vaccination. @RheumNow #EULAR2026 https://t.co/wD0iTDxMEx

• https://x.com/RHEUMarampa/status/2063177556216439274/photo/1

RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r

• Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? | RheumNow